Dissolvable Hydrogel Dressing for the Treatment of Burns
用于治疗烧伤的可溶性水凝胶敷料
基本信息
- 批准号:9010534
- 负责人:
- 金额:$ 39.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-01 至 2019-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdhesivesAnimal ModelAnimalsBiocompatible MaterialsBody SurfaceBurn TraumaBurn injuryBurning PainCaringCharacteristicsChemistryClinicClinicalClinical TrialsCollectionComplexContractsCysteineDataData AnalysesDebridementDevelopmentDevicesEconomicsElasticityEnvironmentEvaluationExcisionExposure toExudateFamilyFamily suidaeFire - disastersFluid BalanceGeneral AnesthesiaGenerationsGoalsHealedHourHumidityHydrogelsImpaired wound healingIn VitroInfectionInjuryKnowledgeLinkLiquid substanceMechanicsModelingMovementNerveOperating RoomsOperative Surgical ProceduresOpioidPainPathologyPatientsPediatric HospitalsPerformancePhysiologicalProcessPropertyRattusReportingRheologyRunningSafetySecondary toSecureSeriesServicesSiteSkinSpecialistSterile coveringsStructure-Activity RelationshipSulfhydryl CompoundsSurfaceSurgeonSurvivorsTestingTimeTissuesToxic effectTranslationsTraumaWound Healingaqueousbasebiomaterial compatibilitydesigndisabilityevaporationexperiencehealingimplantationin vivoin vivo Modelinjurednovelpain receptorprototypepsychologicpublic health relevanceresearch studysocialsubcutaneousthioesterwound
项目摘要
DESCRIPTION: This application describes the synthesis, characterization, and evaluation of a hydrogel dressing that dissolves and can be easily removed from the wound surface of a patient with second degree burns with no further trauma. Burns are one of the most common and devastating forms of trauma. Each year, more than 300,000 people die from fire-related burn injuries and millions suffer from burn-related disabilities and disfigurements with psychological, social, and economic effects on both the survivors and their families. Dressing removal is reported to be the time of most pain (after the burn itself) and opioids continue to be the mainstay of treatment for the burn patient. The duration of a burn dressing change in a typical injury requiring ICU/OR level care is often at least 60 minutes with induction of general anesthesia, which can extend to more than three hours depending on the case. At present, all clinically approved available dressings adhere to the wound surface so that each change of dressing leads to traumatization of newly formed tissues on the outer layer of the body's surface, delayed healing, and great personal suffering for the injured patient. The application describes a thiol- terminated dendron and a bifunctional NHS-activated PEG that react with each other to form a thioester-linked hydrogel dressing that can be subsequently dissolved by exposure of an aqueous thiol solution via a thiol- thiolester exchange mechanism. The proposed experiments will test the hypothesis that a hydrogel- based, dissolvable burn dressing will provide a barrier to infection, promote wound healing, and be easily removable on demand. Importantly, it presents preliminary data demonstrating the synthesis, characterization, and performance of a dissolvable hydrogel dressing prototype. The specific aims of this four- year application are: Aim 1: Synthesize and characterize a series of hydrogel burn dressings; Aim 2: Determine the in vitro toxicity and biocompatibility, as well as in vivo compatibility after subcutaneous implantation of the dissolvable dressing; and Aim 3: Evaluate the efficacy of the dissolvable dressing in vivo.
描述:本申请描述了一种水凝胶敷料的合成、表征和评估,该敷料可以溶解并可以轻松地从二度烧伤患者的伤口表面去除,而不会造成进一步的创伤。烧伤是最常见和最具破坏性的创伤形式之一。据报道,每年有超过 30 万人死于与火灾相关的烧伤,数百万人遭受烧伤相关的残疾和毁容,对幸存者及其家人造成心理、社会和经济影响。最疼痛的时间(烧伤本身之后)和阿片类药物仍然是烧伤患者的主要治疗方法 对于需要 ICU/OR 级别护理的典型损伤,烧伤敷料更换持续时间通常至少为 60 分钟(诱导)。全身麻醉的时间根据情况可以长达三个小时以上。目前,所有临床批准的可用敷料都粘附在伤口表面,因此每次更换敷料都会导致身体外层新生组织的创伤。表面、延迟愈合和该申请描述了一种硫醇封端的树突和一种双功能的 NHS 激活的 PEG,它们相互反应形成硫酯连接的水凝胶敷料,随后可以通过暴露于硫醇水溶液来溶解该敷料。硫醇-硫醇酯交换机制将验证基于水凝胶的可溶解烧伤敷料将提供感染屏障、促进伤口愈合并且易于去除的假设。重要的是,它提供了证明可溶性水凝胶敷料原型的合成、表征和性能的初步数据。这一为期四年的应用的具体目标是: 目标 1:合成和表征一系列水凝胶烧伤敷料;确定可溶性敷料皮下植入后的体外毒性和生物相容性以及体内相容性;目标3:评价可溶性敷料的体内功效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK W. GRINSTAFF其他文献
MARK W. GRINSTAFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK W. GRINSTAFF', 18)}}的其他基金
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
缓释松弛素2治疗肩周炎
- 批准号:
10669219 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别:
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
缓释松弛素2治疗肩周炎
- 批准号:
10443323 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别:
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21:一种用于治疗鳞状细胞肺癌的新型抗体药物偶联物
- 批准号:
10510002 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别:
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
R21:一种用于治疗鳞状细胞肺癌的新型抗体药物偶联物
- 批准号:
10671669 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别:
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation
缺失受体的难题:通过药物受体调节增强功效
- 批准号:
10708018 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别:
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles
使用溶酶体靶向纳米颗粒逆转自噬缺陷的新方法
- 批准号:
9752911 - 财政年份:2019
- 资助金额:
$ 39.18万 - 项目类别:
R21: Acidic Nanoparticles for Restoration of Autophagy in Age-associated NAFLD
R21:酸性纳米颗粒用于恢复年龄相关性 NAFLD 中的自噬
- 批准号:
9902306 - 财政年份:2019
- 资助金额:
$ 39.18万 - 项目类别:
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles
使用溶酶体靶向纳米颗粒逆转自噬缺陷的新方法
- 批准号:
9914192 - 财政年份:2019
- 资助金额:
$ 39.18万 - 项目类别:
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants
聚合物组织润滑剂的合成、表征和评估
- 批准号:
9096649 - 财政年份:2014
- 资助金额:
$ 39.18万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于中医经典名方干预效应差异的非酒精性脂肪性肝病动物模型证候判别研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Tissue Engineered Nigrostriatal Pathway for Anatomical Tract Reconstruction in Parkinson's Disease
组织工程黑质纹状体通路用于帕金森病的解剖束重建
- 批准号:
10737098 - 财政年份:2023
- 资助金额:
$ 39.18万 - 项目类别:
Developing Therapeutic Gel Embolic Agents for Arteriovenous Malformation Embolization
开发用于动静脉畸形栓塞治疗的凝胶栓塞剂
- 批准号:
10667726 - 财政年份:2023
- 资助金额:
$ 39.18万 - 项目类别:
Development of a Novel Bone Adhesive Scaffold to Accelerate Bone Regeneration and Improve Ridge Height Maintenance for the Treatment of Patients with Residual Ridge Resorption
开发新型骨粘合剂支架以加速骨再生并改善牙槽嵴高度维持以治疗残留牙槽嵴吸收的患者
- 批准号:
10603678 - 财政年份:2023
- 资助金额:
$ 39.18万 - 项目类别:
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
组织粘附 RNA 干扰纳米颗粒可阻止创伤后和自发性骨关节炎的进展。
- 批准号:
10539405 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别:
Smart sensor for guiding safe delivery of anesthetic and pain drugs through epidurals
智能传感器用于指导通过硬膜外麻醉剂和止痛药物的安全输送
- 批准号:
10545953 - 财政年份:2022
- 资助金额:
$ 39.18万 - 项目类别: